RVAC Medicines
MRNA platform company engaged in the research and development of innovative products such as vaccines for diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD865m—1.3b (Dealroom.co estimates Apr 2022.)
Singapore (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
* | $140m | Series B | |
| Total Funding | AUD216m | ||